Filing Flows › Sanofi (SNY) › Q4 2025
Sanofi (SNY) Q4 2025 earnings results (fourth quarter 2025)
6-K filed Jan 29, 2026
Sanofi (SNY) reported revenue of $11.3B for the fourth quarter 2025 (Q4 2025), +7% from a year earlier. Operating margin was -9.2%, net loss $794M (7.0% of revenue).
Sanofi, Q4 2025: revenue $11.3B (+7% year over year), operating margin -9.2%, net loss $794M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.3B | — | +7% |
| Operating profit | −$1.0B | — | — |
| Net earnings | −$794M | — | — |
What changed
Revenue was €11.3B in Q4 2025, up 7% year over year.
Gross margin was 74.8%, up 0.5 points from a year earlier. Operating costs exceeded revenue by €1.0B, an operating margin of -9.2%. Operating expenses grew 38% against revenue growth of 7%. The fastest-growing cost line was Other operating costs (+55%). The quarter ended with a net loss of €0.79B. Non-operating items added €0.59B, -133% of pre-tax earnings, so the bottom line overstates operating performance.
Questions
What was Sanofi's revenue in the fourth quarter 2025?
Sanofi (SNY) reported revenue of $11.3B for the fourth quarter 2025 (Q4 2025), +7% from a year earlier.
Was Sanofi profitable in the fourth quarter 2025?
Operating loss was $1.0B (-9.2% of revenue) and net loss $794M.
Source: Sanofi 6-K on SEC EDGAR.